ABBOTT LABORATORIES acquisition history

Abbott acquired EAS, a nutrition company with a portfolio of nationally recognized brands including AdvantEdge, Myoplex and Body for Life. The business expanded Abbott's presence in adult nutrition and consumer performance and weight-management products.

Abbott acquired Spine Next, a manufacturer of orthopedic spinal implant devices, including the Wallis dynamic stabilization system for treating early degenerative disc disease without spinal fusion. The purchase expanded Abbott's spine business (later operated as Abbott Spine).

Abbott acquired TheraSense, a developer and marketer of FreeStyle blood glucose self-monitoring systems known for very small sample sizes, rapid results and less painful testing. TheraSense was combined with Abbott's MediSense business to form Abbott Diabetes Care.

Abbott acquired Visiogen, giving it a next-generation accommodating intraocular lens (IOL) technology (the Synchrony lens) to address presbyopia in cataract patients. The deal built on Abbott's entry into vision care earlier in 2009 through Advanced Medical Optics.

IDEV Technologies, headquartered in Webster, Texas, is a privately held company developing next-generation devices for interventional radiologists, vascular surgeons and cardiologists, including the SUPERA Veritas self-expanding interwoven-nitinol stent for treating peripheral artery disease. Abbott acquired all outstanding equity to expand and complement its peripheral-vascular portfolio of guidewires, balloon catheters and stents.

Cephea Valve Technologies is a privately held medical-device company developing a less-invasive transcatheter mitral valve replacement delivered through a vein in the leg, avoiding open-heart surgery. Abbott had provided capital and secured a purchase option in 2015, and in January 2019 exercised that option to acquire the company, building on its structural-heart portfolio.

Abbott acquired STARLIMS Technologies, a provider of laboratory information management systems (LIMS), adding web-based software that helps laboratories store, retrieve and analyze growing volumes of clinical and operational data. The purchase built Abbott's position in laboratory informatics within its diagnostics business.

Abbott acquired Ibis Biosciences, developer of the Ibis T5000 biosensor system for rapid identification and characterization of infectious agents, from Isis Pharmaceuticals. The purchase expanded Abbott's position in molecular diagnostics for infectious disease.

Exact Sciences is a leader in large and fast-growing cancer screening and precision oncology diagnostics, best known for the Cologuard colorectal cancer screening test and the Oncotype DX cancer recurrence assays. approximately $21 billion equity value (about $23 billion including net debt).

Abbott has repeatedly taken on the world's most challenging health issues and made a meaningful impact on the lives of people in areas such as diabetes, cardiovascular disease and infectious disease. With Exact Sciences, we will do the same in cancer.Robert B. Ford — Chairman and CEO, Abbott

With the legacy and deep expertise of the Exact Sciences team, we're ready to transform cancer care.Abbott management — Exact Sciences completion release

Bigfoot Biomedical develops connected insulin-management solutions, furthering Abbott's efforts to develop connected solutions for making diabetes management more personal and precise.

On September 22, 2023, Abbott completed the acquisition of Bigfoot Biomedical, Inc. (Bigfoot), which will further Abbott's efforts to develop connected solutions for making diabetes management more personal and precise.Abbott FY2023 10-K — Item 1 Business

Cardiovascular Systems, Inc. (CSI) makes an atherectomy system used in treating peripheral and coronary artery disease, adding complementary technologies to Abbott's portfolio of vascular device offerings. $851 million ($20.00 per common share).

On April 27, 2023, Abbott completed the acquisition of Cardiovascular Systems, Inc. (CSI). CSI's atherectomy system, which is used in treating peripheral and coronary artery disease, adds complementary technologies to Abbott's portfolio of vascular device offerings.Abbott FY2023 10-K — Item 1 Business

Walk Vascular is a commercial-stage medical device company with a minimally invasive thrombectomy system designed to remove peripheral blood clots; its peripheral thrombectomy system has been incorporated into Abbott's existing endovascular portfolio.

In September 2021, Abbott acquired Walk Vascular, LLC (Walk Vascular), a commercial-stage medical device company with a minimally invasive thrombectomy system designed to remove peripheral blood clots. Walk Vascular's peripheral thrombectomy system has been incorporated into Abbott's existing endovascular portfolio.Abbott FY2023 10-K — financial statements note

Alere is a global leader in point-of-care diagnostics, providing rapid tests across infectious disease, cardiometabolic and toxicology testing close to the patient. $51 per share, approximately $5.3 billion at close (originally announced at $56 per share / ~$5.8 billion equity value).

We want to offer our customers the best and broadest diagnostics solutions. Alere helps us do that.Miles D. White — Chairman and CEO, Abbott

Our leading platforms and global presence in point-of-care diagnostics, combined with Abbott's broad portfolio of market-leading products, position the combined company for strong growth.Namal Nawana — President and CEO, Alere

St. Jude Medical is a global medical device company with leading positions in cardiac rhythm management, atrial fibrillation, heart failure and neuromodulation. approximately $25 billion equity value ($46.75 cash + 0.8708 Abbott shares per share, ~$85/share; ~$30 billion total value including debt).

Bringing together these two great companies will create a premier medical device business and immediately advance Abbott's strategic and competitive position.Miles D. White — Chairman and CEO, Abbott

Tendyne Holdings is a private medical-device company developing minimally invasive mitral valve replacement therapies; its Bioprosthetic Mitral Valve System is designed to be implanted in a beating heart without open-heart surgery. Abbott acquired the equity it did not already own to broaden its foundation in treatments for mitral valve disease.

Abbott acquired Topera, a developer of electrophysiology technology including a diagnostic catheter and rotor-identification mapping system used to diagnose and treat atrial fibrillation. The deal gave Abbott a foundational entry into the catheter-based electrophysiology market.

There is significant room to use advanced rotor identification technologies to improve the success rate and reduce the need for multiple ablation procedures.John M. Capek — Ph.D., Executive Vice President, Medical Devices, Abbott

Abbott acquired control of Veropharm, a leading Russian pharmaceutical manufacturer, through the purchase of Limited Liability Company Garden Hills, the holding company that owned about 98 percent of Veropharm. The deal established a manufacturing footprint in Russia and added a portfolio of medicines aligned with Abbott's therapeutic focus areas.

CFR Pharmaceuticals is a Latin America-based branded generics pharmaceutical company with a broad portfolio of well-known, trusted products and a strong presence across the fast-growing region. approximately $2.9 billion.

By adding CFR's portfolio of well-known, trusted products, Abbott has taken another key step in actively shaping its portfolio to better meet the evolving needs of health care.Abbott — CFR completion news release

Abbott acquired OptiMedica, maker of the Catalys Precision Laser System for femtosecond laser-assisted cataract surgery. The deal gave Abbott an entry point into the laser cataract surgery market, complementing its existing vision-care and intraocular-lens business.

The acquisition of OptiMedica will provide Abbott with an entry point into the rapidly developing laser cataract surgery market, offering physicians a state-of-the-art, computer-guided alternative for treating patients with cataracts.Murthy Simhambhatla — Senior Vice President, Medical Optics, Abbott

Piramal's Healthcare Solutions business is a leading branded generics pharmaceutical operation in India with a broad product portfolio and extensive local distribution. $2.2 billion up-front plus $400 million annually for four years beginning in 2011 (approximately $3.72 billion total).

Facet Biotech is a biotechnology company with a portfolio of biologic drug candidates, including programs in multiple sclerosis and oncology and an antibody-engineering platform. $27.00 per share in cash (approximately $450 million; net of cash ~$722 million enterprise / ~$450M net).

Solvay Pharmaceuticals is the pharmaceuticals business of the Solvay Group, with a diversified portfolio of branded specialty pharmaceutical products and a strong international, particularly emerging-markets, footprint. EUR 4.5 billion (approximately $6.2 billion) in cash, plus potential additional payments.

Abbott acquired Evalve, a leader in devices for minimally invasive repair of cardiac mitral valves, including the MitraClip catheter-based system. The deal gave Abbott a presence in the growing area of percutaneous treatment for structural heart disease.

Advanced Medical Optics is a leader in eye care, holding the number one position in LASIK surgical devices, number two in the cataract surgical device market and number three in the contact lens care market. $22.00 per share, approximately $2.8 billion including debt.

Kos Pharmaceuticals is a specialty pharmaceutical company focused on cardiometabolic and respiratory products, including the Niaspan and Advicor lipid-management franchises. $78.00 per share in cash (approximately $3.7 billion).

Guidant's vascular intervention and endovascular solutions businesses, including coronary and peripheral stent and angioplasty product lines, acquired from Boston Scientific as a condition of Boston Scientific's acquisition of Guidant. approximately $4.1 billion (acquired from Boston Scientific in connection with its acquisition of Guidant).

i-STAT is the handheld point-of-care platform at the core of Abbott's with-patient blood testing business. The prescription device runs a wide range of blood tests from just two or three drops of a sample and returns lab-quality results in a matter of minutes, letting clinicians test wherever the patient is rather than sending samples to a central lab. Abbott reports the technology is used across a large share of U.S. hospitals, from the ICU and operating room to radiology, and it anchors the company's Point of Care diagnostics franchise, later modernized as the i-STAT Alinity system. $15.35 per share in cash (approximately $392 million).

Abbott acquired ZonePerfect Nutrition Company, a marketer of nutrition bars and other products for active consumers. The brand broadened Abbott's adult and consumer nutrition offering.

Abbott acquired Integrated Vascular Systems, a developer of a novel vessel-closure technology used to seal arterial access sites following catheter-based procedures. The technology strengthened Abbott's vascular device pipeline.

Abbott acquired Spinal Concepts, a marketer of spinal fixation products used to treat spinal disorders, diseases and injuries. The deal built out Abbott's orthopedic spine portfolio.

Abbott acquired the assets of JOMED N.V.'s coronary and peripheral interventional business, adding stents and related interventional cardiology and vascular products. The purchase helped form the basis of Abbott's vascular device operations.

Vysis is a genomic disease management company specializing in molecular cytogenetic and FISH-based diagnostic products for cancer and genetic disease. $30.50 per share in cash (approximately $355 million).

BASF's pharmaceutical business, operated as Knoll Pharmaceuticals, including the global operations and an early-stage anti-inflammatory antibody (later commercialized by Abbott as HUMIRA). approximately $6.9 billion in cash.